Key Highlights

  • Shares of Soleno Therapeutics (SLNO) climbed more than 30% during premarket hours Monday following acquisition reports
  • Neurocrine Biosciences (NBIX) has entered advanced discussions to purchase Soleno for a valuation exceeding $2.5 billion
  • The proposed transaction could price SLNO shares in the low-to-mid $50 range
  • According to the Financial Times, an agreement may be reached as early as Monday, April 6
  • Shares of Neurocrine declined 0.4% premarket following the announcement

Soleno Therapeutics experienced challenging market conditions throughout 2026, recording a decline of approximately 14% year to date before Monday’s dramatic reversal.


SLNO Stock Card
Soleno Therapeutics, Inc., SLNO

According to a Financial Times report, Neurocrine Biosciences has progressed to late-stage negotiations for acquiring the rare disease-focused biotechnology company in a transaction valued above $2.5 billion. The news triggered a premarket rally exceeding 30% for SLNO shares.

The proposed acquisition would establish Soleno’s valuation in the low-to-mid $50s per share range. Negotiations are advancing rapidly, with the FT indicating that both parties could finalize terms as early as Monday.

Soleno’s primary commercial product is Vykat XR, which the company introduced to market last year for treating hyperphagia—a medical condition associated with Prader-Willi syndrome. Hyperphagia produces severe, unrelenting hunger that can trigger dangerous complications such as stomach rupture, choking incidents, obesity, and cardiovascular disease.

Prader-Willi syndrome represents a rare genetic disorder that affects approximately one in 15,000 live births. Vykat XR became the first commercially approved medication designed to address the hunger-driven symptoms characteristic of this condition.

Industry analysts have projected that Vykat XR could achieve peak annual revenues reaching $2.3 billion—a sales potential that appears to have attracted significant interest from Neurocrine.

Neurocrine Expands Into Rare Disease Territory

Neurocrine presently maintains a market capitalization approaching $13.21 billion. The company’s existing product lineup features Ingrezza, a treatment for involuntary movements associated with Huntington’s disease, alongside several additional approved therapies and developmental candidates.

Acquiring Vykat XR would establish Neurocrine’s presence within the rare disease and orphan drug market, a segment characterized by robust pricing dynamics and reduced competitive pressures.

Shares of Neurocrine experienced a modest 0.4% decline during premarket trading Monday. This response commonly occurs when acquiring companies announce major purchases, as investors factor in the premium being offered.

SLNO’s Performance Leading Up to the News

Despite Monday’s surge, SLNO had recorded a 14% decline in 2026 prior to this week’s developments. The stock had underperformed despite analyst enthusiasm regarding Vykat XR’s revenue-generating prospects.

According to TipRanks data, SLNO carries a Strong Buy consensus rating from 11 analysts. The average price target stands at $101.09, while the highest projection reaches $125.

With the reported deal pricing shares in the low-to-mid $50s range, the acquisition would materialize significantly below analyst price targets—while still delivering a considerable premium over SLNO’s recent trading levels.

The Financial Times report referenced sources with knowledge of the negotiations, emphasizing that discussions are advancing favorably and approaching a potential finalized agreement.